Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

The U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to 50 years. (1) ...

Vaccination is extremely crucial in reducing morbidity and mortality by protecting billions of people every year from infectious diseases. The key reason the adult population has grown significantly ...

The ongoing final stage aims to assess the vaccine in nearly 750 infants. Credit: Gorodenkoff / Shutterstock. Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

or any time before or after administration of other vaccines, including COVID-19 and pneumococcal vaccines. Data are limited regarding concurrent administration of newer adjuvanted influenza vaccines ...